ASPiRATION – An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients.

CHALLENGE
Lung cancer is the leading cause of cancer death in Australia and worldwide, with a five-year survival rate of only 17 per cent.

STUDY
The ASPiRATION program is a pioneering 5-way partnership between Government, industry, and academia. The program is led by the Thoracic Oncology Group of Australasia (TOGA) [and formerly the Australasian Lung Cancer Trials Group (ALTG)], in collaboration with the Australian Genomic Cancer Medicine Centre (AGCMC) and the NHMRC Clinical Trials Centre (CTC).

The program is jointly funded by the federal government’s Medical Research Future Fund (MRFF) and Roche, as well as in-kind support through access to Roche medicines in 4 of the program’s therapeutic clinical trials.

IMPACT
The ASPiRATION study is the first of its kind in Australia to generate high-quality, real-world data about the impact and value of comprehensive genomic profiling (CGP) to deliver precision medicine and personalised healthcare, by identifying actionable molecular targets and treating these patients in a suite of therapeutic substudies using novel targeted treatments.

PROGRESS
Molecular screening for ASPiRATION commenced in late 2020. Five therapeutic substudies opened in 2021, and a sixth related clinical trial started in 2022, all developed in partnership between TOGA and CTC, and supported by funding and in-kind support through access to medicines from various industry partners.

See ACTRN for full trial details >